News

May 21, 2019

A recording of our May 15 webinar, Update on FVIII Inhibitor Testing and Introduction to the CRYOcheck™ Factor VIII Inhibitor Kit with guest speaker Connie H. Miller, PhD, is now available on Our Webinars page.

May 03, 2019

Heading to Vancouver for ISLH May 9-11? If so, we’d love to see you. Drop by and visit Precision BioLogic and Affinity Biologicals at booth 503.

April 21, 2019

Lab Week. In Canada, it's National Medical Laboratory Week. In the U.S., it's Medical Laboratory Professionals Week. No matter what you call it, it's a time to recognize clinical laboratory professionals and all that they bring to their vital role in health care. 

Lab Week runs April 21–27 this year. In support, we're hosting a FREE WEBINAR next month:

April 12, 2019

April 17 is World Hemophilia Day and Precision BioLogic is proud to support this important World Federation of Hemophilia initiative. This year, the focus is on outreach and identification as the “first step to care." Visit worldhemophiliaday.org to share your stories of diagnosis along with efforts to increase outreach and identification.

March 13, 2019

Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce FDA 510(k) clearance and the launch of its CRYOcheck™ Factor VIII Inhibitor Kit in the U.S. This clearance follows approvals received from regulatory authorities in Canada, the European Union, Australia, and New Zealand, where the kit launched in February of this year.

February 11, 2019

Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce the availability of its new CRYOcheck™ Factor VIII Inhibitor Kit in Canada, the European Union, Australia, and New Zealand following market authorization by Health Canada and respective in-country regulatory authorities last month.

January 02, 2019

2019 is upon us and we're gearing up for an eventful year. Check out our updated list of conferences. We hope to see you there!

December 03, 2018

On December 1, Precision BioLogic unveiled data from a study using a new kit for a Modified Nijmegen-Bethesda Assay (MNBA) at the 60th ASH Annual Meeting in San Diego, CA.

November 14, 2018

Please note that Precision BioLogic will be closed December 22 to January 1. We will reopen the morning of January 2, 2019.

To avoid potential shipping delays during the holidays, please contact us by December 14 if you will need to order any of our products before the new year.

November 01, 2018

HALIFAX, November 1, 2018—Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce the completed acquisition of Affinity Biologicals Inc., a primary manufacturer of reagents and kits used in hemostasis and thrombosis research and diagnostics.

October 23, 2018

Members of the Precision BioLogic team will be at the following events:

Clinical and Laboratory Update in Thrombosis and Anticoagulation
Oct 31–Nov 2 in Scottsdale, AZ

Maritech 2018
Nov 1–3 in Halifax, NS

We'd love to see you. If you are attending either of these events, please be sure to drop by our booth and say hello.

October 04, 2018

The countdown is on! Do you know thrombosis? Learn more at worldthrombosisday.org

We support World Thrombosis Day

July 19, 2018
Precision BioLogic today unveiled data from a study using a new kit for a Modified Nijmegen-Bethesda Assay (MNBA) at the International Society on Thrombosis and Haemostasis’ Scientific and Standardization Committee (SSC) meeting in Dublin.
May 18, 2018
Precision BioLogic will present data at the World Federation of Hemophilia (WFH) 2018 World Congress in Glasgow, Scotland, May 20-24. Recognizing the need to improve Factor VIII (FVIII) inhibitor testing for people with hemophilia A, the company studied the agreement between a chromogenic Modified Nijmegen-Bethesda Assay (MNBA) and a qualitative ELISA test in the detection of FVIII inhibitors in plasma samples.
April 22, 2018

April 22-28 is lab week! Precision BioLogic salutes medical laboratory professionals working behind the scenes, conducting tests that guide more than 70% of medical decisions*. The tests these healthcare detectives conduct save time, costs, and lives by enabling early detection and prevention of disease.

Pages